Catalyst Biosciences, Inc. (NasdaqCM:CBIO) Signed Agreements to acquire 65.2% stake in Catalyst Biosciences, Inc. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc. for approximately CNY 3.8 billion on December 26, 2022. CBIO?s current management team, Nassim Usman as CEO and Seline Miller as CFO, will continue to serve in their positions, respectively, at least through the closing of the Continent acquisition. Effective with the closing of the F351 acquisition, Ying Luo and Thomas Eastling will be joining the Catalyst board representing the Group, along with the three legacy Catalyst directors (Augustine Lawlor, Nassim Usman.

Ph.D., and Andrea Hunt). Catalyst may be required to pay a termination fee of (CNY 13.73 million). Closing of the transactions contemplated under the Business Combination Agreement will be subject to Catalyst stockholder approval at a stockholder meeting expected to be held in the second quarter of 2023 and Nasdaq's approval of the listing of the shares of Catalyst Common Stock to be issued in connection with the contributions.

As of September 1, 2023, GNI Group announced that the stockholder meeting of Catalyst held on August 29, 2023, all the agenda items related to the transaction between GNI Group and Catalyst Biosciences, Inc. have been passed. The deal is expected to be completed in Mid 2023. The deal is expected to close in the third quarter of 2023.

As of December 29, 2022, Lifshitz Law PLLC will investigate possible breach of fiduciary duties in connection with the merger of CBIO and GNI Group Ltd. Raymond James is serving as exclusive financial advisor to Catalyst and Orrick, Herrington & Sutcliffe LLP is serving as legal counsel to Catalyst. Gibson, Dunn & Crutcher LLP is serving as legal counsel to GNI.